MX2016001032A - Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. - Google Patents

Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.

Info

Publication number
MX2016001032A
MX2016001032A MX2016001032A MX2016001032A MX2016001032A MX 2016001032 A MX2016001032 A MX 2016001032A MX 2016001032 A MX2016001032 A MX 2016001032A MX 2016001032 A MX2016001032 A MX 2016001032A MX 2016001032 A MX2016001032 A MX 2016001032A
Authority
MX
Mexico
Prior art keywords
compositions
methods
desmopressin
combination
reductase inhibitor
Prior art date
Application number
MX2016001032A
Other languages
English (en)
Spanish (es)
Inventor
H Fein Seymour
Herschkowitz Samuel
Cheng Linda
CHENG Maria
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2016001032A publication Critical patent/MX2016001032A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016001032A 2013-07-23 2014-07-23 Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. MX2016001032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857428P 2013-07-23 2013-07-23
PCT/US2014/047897 WO2015013453A1 (en) 2013-07-23 2014-07-23 Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor

Publications (1)

Publication Number Publication Date
MX2016001032A true MX2016001032A (es) 2017-10-31

Family

ID=51299054

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001032A MX2016001032A (es) 2013-07-23 2014-07-23 Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.

Country Status (9)

Country Link
US (1) US9925232B2 (enExample)
EP (1) EP3024473A1 (enExample)
JP (3) JP2016525147A (enExample)
KR (3) KR20240015736A (enExample)
CN (1) CN105579056A (enExample)
AU (1) AU2014293140A1 (enExample)
CA (1) CA2919194A1 (enExample)
MX (1) MX2016001032A (enExample)
WO (1) WO2015013453A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
JP2017535567A (ja) 2014-11-20 2017-11-30 アラーガン、インコーポレイテッドAllergan,Incorporated アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4505616A (en) 1983-05-26 1985-03-19 Litton Systems, Inc. Self-locking chock system for a jack-up rig unit
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
EP1689419A4 (en) * 2003-11-10 2009-01-14 Reprise Biopharmaceutics Llc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW DOSAGE DESMOPRESSIN
ES2348303T3 (es) 2003-12-08 2010-12-02 Cpex Pharmaceuticals, Inc. Composiciones farmacauticas y procedimientos de tratamiento con insulina.
CA2633570A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
CA2695634C (en) * 2007-08-06 2018-01-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
WO2010075327A1 (en) 2008-12-22 2010-07-01 Serenity Pharmaceuticals Corporation Desmopressin composition
PT2381923T (pt) * 2008-12-22 2018-11-13 Serenity Pharmaceuticals Llc Administração intranasal de desmopressina
CN102647993A (zh) * 2009-06-18 2012-08-22 阿勒根公司 安全的去氨加压素给药
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物

Also Published As

Publication number Publication date
JP2016525147A (ja) 2016-08-22
KR20160034366A (ko) 2016-03-29
CA2919194A1 (en) 2015-01-29
KR20240015736A (ko) 2024-02-05
EP3024473A1 (en) 2016-06-01
CN105579056A (zh) 2016-05-11
JP2020114858A (ja) 2020-07-30
US9925232B2 (en) 2018-03-27
US20150031614A1 (en) 2015-01-29
AU2014293140A1 (en) 2016-03-03
JP2022137252A (ja) 2022-09-21
KR20210103590A (ko) 2021-08-23
WO2015013453A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
IL277917B (en) jak2 and alk2 inhibitors and their use
IL272910A (en) Ectonucleotide pyrophosphate-phosphodiesterase 1 (ENPP-1) inhibitors and their uses
HRP20190270T1 (hr) C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze
HUE039504T2 (hu) Kináz inhibitor és alkalmazása
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
EP2968340A4 (en) COMBINING KINASE INHIBITORS AND USES THEREOF
MX2016001030A (es) Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
IL240553A0 (en) il-1ß inhibitory compounds and use thereof
IL267238A (en) The paranase inhibitors and their use
HUE046190T2 (hu) GATA-3 inhibitorok TH2-vezérelt asztma kezelése során történõ alkalmazásra
MX2016001032A (es) Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.
IL267243A (en) The paranase inhibitors and their use
SI3024825T1 (sl) Imidazolkarboksamidi in njihova uporaba kot faah inhibitorji
MX2017006655A (es) Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico.
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
GB201321353D0 (en) Transformer tapping arrangement and methods of operation of same
MY168958A (en) Intermediates and processes for preparing compounds